Jujuboside A ameliorates T2DM-associated MASH: Suppression of YY1/FAS axis-mediated hepatic de novo fatty acid biosynthesis.
Metabolic dysfunction-associated steatohepatitis (MASH) in type 2 diabetes mellitus (T2DM) represents a progressive subtype of metabolic dysfunction-associated steatotic liver disease (MASLD), and is predominantly driven by dysregulated hepatic fatty acid (FA) metabolism. Although Jujuboside A (Ju A), a major bioactive...